Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb open-label single-arm study of BPC2001 for prevention of acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation
CTR20253502Phase 2Active
- Sponsor
- Sunfu Biomedical
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inolimomab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Sunfu Biomedical. Started Oct 2025; status: active.
02
Drugs
inolimomab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on CTR20253502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253502.